NCT07147894 Executive Function Training for Children and Adolescents
| NCT ID | NCT07147894 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northeastern University |
| Condition | Cognitive Change |
| Study Type | INTERVENTIONAL |
| Enrollment | 780 participants |
| Start Date | 2025-12-14 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 780 participants in total. It began in 2025-12-14 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate how different approaches to executive function (like adding game-like features, varying the number of tasks, and providing coaching) can enhance executive function outcomes in adolescents with and without ADHD. The main questions it aims to answer are: * What components of executive function training contribute most to improving outcomes? * How do training components vary in their impacts on adolescents diagnosed with ADHD compared to those without a diagnosis? * What individual characteristics influence the effectiveness of executive function training? Researchers will test six different training setups to examine which setups are the most effective for different people. They will evaluate both how well participants follow the training schedule and whether there are changes in psychological and cognitive outcomes after training. Participants will complete: * 40 training sessions over 4 weeks * A set of tests and surveys before and after the training * Follow-up assessments and surveys 6 months after finishing the training
Eligibility Criteria
Inclusion Criteria: * 12-17 years old. * Child must have a caregiver (parent/guardian) who is available to participate as a training aide. * Child and parent/caregiver are able to understand/speak adequate English or Spanish to follow and participate in study procedures * Both child and parent/guardian are willing to give informed consent/assent, be randomized to either intervention condition, and be willing to follow the assigned study protocol. * \~50% of the participants: Meet criteria for ADHD DSM-5 diagnosis. Exclusion Criteria: * Child is taking ADHD medication/stimulants. * Child has been formally identified as intellectually disabled. * Abnormal visual acuity or hearing challenges that are prohibitive to participating in the intervention/assessment. * History of organic mental disorders (conditions or disturbances that may be caused by injuries and/or neurodegenerative diseases affecting brain tissues), psychosis, history of autism spectrum disorders, intellectual disability, or active substance use or suicidal ideation (such individuals will be referred to psychiatric services). * Major sensory or motor impairment that would preclude valid cognitive testing. * Participants with color blindness, if they are unable to discriminate the task relevant stimuli. * Populations considered vulnerable such as wards and those with neurological or other health conditions that may prevent the ability to give informed consent.
Contact & Investigator
Aaron Seitz, PhD
PRINCIPAL INVESTIGATOR
Northeastern University
Frequently Asked Questions
Who can join the NCT07147894 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 17 Years, studying Cognitive Change. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07147894 currently recruiting?
Yes, NCT07147894 is actively recruiting participants. Contact the research team at a.carrillo@northeastern.edu for enrollment information.
Where is the NCT07147894 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07147894 clinical trial?
NCT07147894 is sponsored by Northeastern University. The principal investigator is Aaron Seitz, PhD at Northeastern University. The trial plans to enroll 780 participants.